Eli Lilly Stock Drops After Earnings. Its Guidance Disappoints.

📆 11/2/2023 6:31 AM
📰 MarketWatch

⏱ Reading Time:
26 sec. here
2 min. at publisher
📊 Quality Score:
News: 14%
Publisher: 97%

United States News News

United States United States Latest News,United States United States Headlines

The drugmaker slashes its guidance for full-year earnings to a range of $6.50 to $6.70 a share, having raised its outlook in August to a range of $9.70 to...

Eli Lilly stock slipped on Thursday after the drugmaker significantly slashed its full-year earnings guidance on the back of a deal spree.

What disappointed was the outlook. Lilly slashed its guidance for full-year earnings to a range of $6.50 to $6.70 a share, having raised its outlook in August to a range of $9.70 to $9.90. “Lilly had another strong quarter in Q3 as Mounjaro and Verzenio continued to gain momentum,” David A. Ricks, the group’s chairman and CEO, said in a statement. “Lilly executed on business development priorities in the third quarter including multiple acquisitions that expand our already robust pipeline.”

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

Write Comment

United States United States Latest News, United States United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Eli Lilly Stock Slumps as Earnings Guidance Slashed DramaticallyLilly slashes its guidance for full-year earnings to a range of $6.50 to $6.70 a share, having raised its outlook in August to a range of $9.70 to $9.90.
Source: MarketWatch - 🏆 3. / 97 Read more »